Human leukocyte antigen (HLA) plays a significant role in the ability of the immune system to recognize and remove invasive, foreign, infected, and malfunctioning cells to fight disease and maintain overall health. HLA mutations can produce aberrant immune response and have been associated with autoimmune disorders, cancer, transplant rejection, and drug sensitivity. Sequencing the HLA region can provide critical insight into various immune disorders. Unfortunately, HLA sequencing has been difficult due to the high levels of sequence homology and dense variability found within this region of the genome. Using proven Illumina next-generation sequencing (NGS) technology, we can generate unambiguous, phase-resolved HLA sequencing results for 11 HLA loci.
We offer HLA typing with Illumina TruSight® HLA v2 Sequencing Panel, which provides unambiguous, phase-resolved HLA typing in a single assay using proven Illumina NGS technology.
The Sequencing Panel covers all commonly typed HLA loci, plus those with emerging relevance:
Loci Target Sequence
HLA-A: 4.1 kb (entire gene)
HLA-B: 2.8 kb (exon 1 — intron 6)
HLA-C: 4.2 kb (entire gene)
HLA-DRB1/3/4/5: 4.6 — 5.1 kb (exon 2 — intron 4)
HLA-DQB1: 6.9 kb (entire gene)
HLA-DPB1: 9.7 kb (exon 2 — 3' UTR)
HLA-DQA1: 7.3 kb (entire gene)
HLA-DPA1: 10.3 kb (entire gene)
Please contact us for more information!